Verily

Verily
Name	Verily Life Sciences
Type	Subsidiary
Foundation	2015
Founder	Alphabet Inc.; originated from Google X
Location	South San Francisco, California, United States
Key people	Andy Conrad; Andy Conrad (former), Adeel A. Malik (CEO)
Industry	Biotechnology; Pharmaceutical research; Medical device development
Parent	Alphabet Inc.

Verily is a biomedical research and engineering company within Alphabet Inc. focused on applying data analytics, hardware engineering, and population studies to problems in healthcare and biomedicine. The company develops diagnostic devices, clinical research platforms, and large-scale population studies in collaboration with pharmaceutical companies, academic institutions, and healthcare systems. Verily aims to bridge engineering from Silicon Valley with translational research from leading universities and research hospitals.

History

Verily traces its origins to teams within Google X working on life sciences and bioinformatics projects alongside efforts at Google. The company was formally announced as an independent subsidiary in 2015 under Alphabet Inc. management, following organizational changes at Google and the creation of Alphabet. Early milestones included recruitment from institutions such as Stanford University, Massachusetts Institute of Technology, and Harvard Medical School. Verily expanded through collaborations with pharmaceutical firms like GlaxoSmithKline, Novartis, and Sanofi, and healthcare organizations such as Mayo Clinic and University of California, San Francisco. Over time Verily launched population studies and device pilots, participated in public health initiatives with Californian and federal partners, and restructured leadership and project portfolios in response to regulatory and commercial challenges.

Organization and Leadership

Verily operates as a subsidiary under Alphabet Inc. and reports to the Alphabet Board of Directors. Leadership has included executives transitioning from Google engineering and leaders recruited from biotechnology and pharmaceutical sectors. Senior management historically featured executives with backgrounds at Genentech, Pfizer, GlaxoSmithKline, and academic research centers such as Johns Hopkins University and UCSF. The corporate structure comprises research divisions, hardware engineering teams, clinical operations, regulatory affairs, and business development groups that interface with partners including Novartis, Sanofi, GlaxoSmithKline (GSK), Cleveland Clinic, and multinational consortia.

Products and Technologies

Verily has developed a portfolio combining wearable sensors, diagnostic hardware, software platforms, and data-analytics tools. Notable projects included a line of smart contact lenses explored with Novartis for glucose monitoring, a continuous glucose monitoring prototype, and wearable devices for cardiovascular monitoring developed with partners such as Google Fit initiatives and academic collaborators. Verily’s software offerings include clinical trial platforms and population-health data systems used in studies like Project Baseline, which aggregated biospecimens and longitudinal health metrics from cohorts in collaboration with institutions including Duke University, Mount Sinai Health System, and Scripps Research. Verily also built hardware for surgical robotics research and laboratory automation, and developed analytics pipelines leveraging techniques from machine learning groups tied to DeepMind research and Google AI.

Research and Partnerships

Verily conducts translational research through alliances with pharmaceutical corporations, academic medical centers, and public-health agencies. Key partnerships have included strategic alliances with GlaxoSmithKline for immune-oncology projects, a joint venture with Sanofi for clinical development, and collaborations with Mayo Clinic and Stanford Health Care on digital health studies. Verily’s Project Baseline involved collaboration with research institutions such as Duke University and Scripps Research to create large-scale cohorts for biomarker discovery. The company has worked with federal and state entities on population surveillance and deployed analytics in partnership with organizations like Centers for Disease Control and Prevention and industry partners including Johnson & Johnson for device validation.

Business Model and Funding

As a subsidiary of Alphabet Inc., Verily’s funding is primarily internal capital allocation supplemented by partner-funded ventures and joint ventures that share investment and commercialization risk with pharmaceutical companies such as Novartis and Sanofi. Revenue streams have included research contracts, licensing of technology, clinical trial services, and co-development agreements. Verily engaged in joint ventures and spin-outs to commercialize assets, sometimes transferring programs to partners or newly formed companies backed by venture investment and corporate partners including GV (company) and strategic corporate investors from the pharmaceutical industry.

Controversies and Criticism

Verily has faced scrutiny over data privacy, commercialization of health data, and the ethics of large-scale population studies, drawing commentary from policy groups, privacy advocates, and academic ethicists. Collaborations with government entities and healthcare systems prompted debates similar to those affecting other technology-health partnerships such as Palantir Technologies and Amazon Web Services engagements in health data. Specific projects—such as wearable device pilots and data-aggregation initiatives—attracted regulatory attention from agencies comparable to Food and Drug Administration scrutiny of medical device validation. Critics have also raised concerns about market concentration and the influence of large technology companies in clinical research environments long dominated by academic and pharmaceutical institutions.

Category:Biotechnology companies of the United States Category:Alphabet Inc. subsidiaries